+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Extracorporeal CO2 Removal Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5616739
The Extracorporeal CO2 Removal Devices Market is projected to register a CAGR of 5.1% during the forecast period.

During the COVID 19 pandemic, the extracorporeal CO2 removal devices market was adversely affected due to supply chain issues. Various research and clinical trials have been conducted on the application of extracorporeal CO2 removal devices on COVID patients. For instance, in September 2021, a study was conducted to investigate the efficacy of extracorporeal CO2 removal for correction of hypercapnia in coronavirus disease 19 (COVID-19)-associated acute respiratory distress syndrome. According to the study, the prevalence of acute respiratory distress syndrome (ARDS) caused by COVID-19 is approximately 8%. Lung-protective ventilation is the current standard of care for ARDS. It limits lung and distal organ impairment but is associated with hypercapnia in approximately 14% of patients with mild to moderate ARDS and almost all patients with severe ARDS. In this setting, early implementation of an extracorporeal CO2 removal (ECCO2R) therapy may prevent further escalation of invasiveness of therapy (e.g., need for extracorporeal membrane oxygenation (ECMO)). A number of low-flow ECCO2R devices are now available, and some of those can be integrated into a renal replacement therapy (RRT) platform. Similarly, in September 2020, a research study was published titled "Extracorporeal multiorgan support including CO 2-removal with the ADVanced Organ Support (ADVOS) system for COVID-19: A case report" stated that in the context of secondary pulmonary infection and progressive liver failure, the patient had a sudden cardiac arrest. Irrespective of the outcome, the study concluded that extracorporeal CO2 removal and multiorgan support were feasible in the COVID-19-patients. Such clinical trials and studies would provide insight into the application of extracorporeal CO2 removal devices on COVID patients. Thus, the market will grow post-pandemic.

Increasing cases of respiratory emergencies and chronic obstructive pulmonary disease (COPD), and other diseases are the major factors augmenting the market growth. For instance, as per the September 2020 report from the University of Manchester students Emily Hammond and Charles McDonald, the estimated global prevalence of COPD was 552,300,599 people, of which 339,206,893 (8.58%) in Asia, 85,278,783 (8.52%) in the Americas, 64,298,051 (5.37%) in Africa, 59,484,329 (7.77%) in Europe and 4,032,543 (10.86%) in Oceania, and an estimated 57,991,563 people with COPD have been admitted to hospital annually. The increasing prevalence of other respiratory disorders such as asthma, cystic fibrosis, lung cancer, and others is further expected to complement the growth of the studied market over the years. For instance, according to the May 2021 update of the World Health Organization, asthma affected about 262 million people in 2019 all over the world and was responsible for about 461,000 deaths globally. According to the Globocan 2020 report, lung cancer was the second most prevalent cancer around the world, and in 2020, 2,206,771 new cases of lung cancer were diagnosed all over the world, and 1,796,144 people died because of it. Also, as per the same report, the five-year prevalence of lung cancer was 2,604,791 people in 2020.

Thus, the high incidence of chronic obstructive pulmonary diseases and other respiratory disorders around the world are expected to boost the growth in the market during the forecast period of the study.

Key Market Trends

Chronic obstructive pulmonary disease (COPD) is Expected to Hold a Significant Market Share Over the Forecast Period

Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening lung disease that causes breathlessness (initially with exertion) and predisposes to exacerbations. Moreover, serious illnesses may lead to the increasing need for emergency treatment for prolonged illnesses and protracted treatment associated with target diseases, and increasing cases of respiratory emergencies and chronic obstructive pulmonary disease (COPD) are the major factors driving growth in the market over the forecast period. According to a research study published in February 2021, titled “Burden of COPD among population above 30 years in India: protocol for a systematic review and proposed meta-analysis”, the estimated overall prevalence of COPD in the low- and middle-income countries was 9.2%, and meta-analysis revealed that the prevalence of COPD among the people of age 30 years and more was 10.6% in low- and middle-income countries. Also, as per the June 2021 report of the World Health Organization, COPD was responsible for 3.23 million deaths in 2019 around the world and about 80% of these deaths were reported in low- and middle-income countries, which suggests the high prevalence of COPD in the low- and middle-income countries and high growth of the studied market is expected in these regions over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

The extracorporeal CO2 removal devices market in North America is expected to grow owing to the factors such as the COVID-19 pandemic, coupled with increasing incidences of respiratory disorders, COPD, increasing government initiatives, and a well-developed healthcare system.

As per the statistics by the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System 2019, the age-adjusted prevalence of COPD varied considerably by state, from less than 4.5% in California, Colorado, Hawaii, Massachusetts, Minnesota, and Utah to more than 9% in Alabama, Arkansas, Kentucky, and West Virginia. As per the same above-mentioned source, states with the highest COPD prevalence were clustered along Ohio and lower Mississippi Rivers in 2019. Similarly, as per the April 2021 statistics by the Asthma and Allergy Foundation of America, about 20 million adults aged 18 years or above in the United States have asthma. Similarly, As per the 2021 estimates by Statistics Canada, in 2020, the number of people aged 35 to 49 years suffering from the chronic obstructive pulmonary disease (COPD) disease was 57,300; 50 to 64 years were 285,300; 65 years and above were 488,100. Thus, the prevalence of such disorders in these countries indicates a consistent demand for extracorporeal CO2 removal devices in the country, thereby contributing to the market growth in the region.

Similarly, clinical trials are one of the factors for the growth of the region. For instance, in September 2021, ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, enrolled 100 patients in the United States-based VENT-AVOID pivotal trial. The VENT-AVOID pivotal trial is currently the world’s largest trial ever conducted on the utilization of ECCO2R in AE-COPD, with 100 patients now enrolled. Such trails provided insight into the upcoming technologies and increased growth in the region.

Hence, due to the above-mentioned factors, the market is likely to grow in the future.

Competitive Landscape

In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Medtronic, Getinge AB, Xenios AG, Alung Technologies, and ESTOR S.P.A, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Numbers of Product Launches and Approvals
4.2.2 Increasing Prevalence of COPD and Other Diseases
4.3 Market Restraints
4.3.1 Risks of Complications During Extracorporeal CO2 Removal Therapy
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product
5.1.1 Extracorporeal CO2 Devices
5.1.2 Disposables
5.1.3 Others
5.2 Application
5.2.1 Chronic Obstructive Pulmonary Disease (COPD)
5.2.2 Acute Respiratory Distress Syndrome (ARDS)
5.2.3 Bridge to Lung Transplant
5.2.4 Others
5.3 End User
5.3.1 Hospitals and Clinics
5.3.2 Ambulatory Surgical Centers
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Alung Technologies
6.1.2 ESTOR S.P.A
6.1.3 Getinge AB
6.1.4 Medica Spa
6.1.5 Medtronic
6.1.6 X-COR Therapeutics
6.1.7 Xenios AG

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alung Technologies
  • Getinge AB
  • Medica Spa
  • Medtronic
  • X-COR Therapeutics
  • Xenios AG